FOLFOXIRI plus cetuximab as conversion therapy for unresectable RAS/BRAF wild-type left-sided colorectal cancer with liver-limited metastases: a prospective dual-center pilot study

FOLFOXIRI plus cetuximab as conversion therapy for unresectable RAS/BRAF wild-type left-sided colorectal cancer with liver-limited metastases: a prospective dual-center pilot study

PurposeTo explore the efficacy and safety of FOLFOXIRI plus cetuximab regimen as conversion therapy for patients with unresectable RAS/BRAF wild-type colorectal liver-limited metastases (CLM).Patients and methodsThis was a dual-center, phase II trial with the rate of no evidence of disease (NED) ach...

Full description

Bibliographic Details
Main Authors: Wenwei Yang, Dong Chen, Yaru Niu, Guifu Wu, Zhangkan Huang, Xinyu Bi, Hong Zhao, Xu Che, Yongkun Sun
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-04-01
Series:Frontiers in Oncology
Subjects:
metastatic colorectal cancer
FOLFOXIRI
cetuximab
liver metastases
conversion therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1375906/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1375906/full

Similar Items